Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02959151

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

A Single-arm Pilot Clinical Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Sponsor: Shanghai Cancer Hospital, China

Conditions Carcinoma, Hepatocellular Colorectal Cancer Metastatic Pancreatic Cancer Metastatic

Interventions CAR-T cell

Updated 6 times since 2017 Last updated: Nov 7, 2016 Started: Jul 31, 2016 Primary completion: Jan 31, 2018 Completion: Jul 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02959151, this PHASE1/PHASE2 trial focuses on Carcinoma, Hepatocellular and Colorectal Cancer Metastatic and remains ongoing. Sponsored by Shanghai Cancer Hospital, China, it has been updated 6 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Dec 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Dec 2018 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Cancer Hospital, China
Shanghai GeneChem Co., Ltd.

Data source: Shanghai GeneChem Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China